Clinical Trial Update: A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 [Phase 3]

View source ↗

Summary

Phase 3 tolerability study in relapsing remitting multiple sclerosis (RRMS) completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• ALKS 8700 (ALKS 8700)

Snippet

Sponsor: Biogen | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2020-07-14